Acute Gastric Variceal Bleeding: Endoscopic Treatment Versus BRTO

Not Applicable

• Conditions: Gastric Varices
• Interventions: Procedure: Balloon-occluded retrograde transvenous obliteration; Procedure: Endoscopic cyanoacrylate injection; Drug: Lauromacrogol; Drug: N-butyl-2-cyanoacrylate

• Registration Number: NCT02468167
• Lead Sponsor: West China Hospital

Brief Summary

The purpose of this study is to study the efficacy of endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration in the management of acute gastric bleeding.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-06
• Study First Submitted: 2015-06-03
• Study First Submitted QC: 2015-06-05
• Study First Posted: 2015-06-10
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-07
• Last Update Posted: 2019-01-08
• Primary Completion: 2020-07
• Study Completion: 2020-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

1. Cirrhosis
2. Active bleeding from gastric varices (GOV2 or IGV1)
3. Presence of gastrorenal shunt

Read More

Exclusion Criteria

1. Previous pharmacologic therapy combined with endoscopic treatment to prevent rebleeding
2. Previous use of TIPS or surgical shunt
3. Non-cirrhotic portal hypertension
4. Contraindications to cyanoacrylate injection or BRTO
5. Portal cavernoma
6. Hepatorenal syndrome
7. Proven malignancy including hepatocellular carcinoma
8. End-stage renal disease under renal replacement therapy;
9. Cardiorespiratory failure
10. Pregnancy or patients not giving informed consent for endoscopic procedures

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
BRTO	Balloon-occluded retrograde transvenous obliteration	Balloon-occluded retrograde transvenous obliteration
NBCA	Endoscopic cyanoacrylate injection	Endoscopic cyanoacrylate injection
BRTO	Lauromacrogol	Balloon-occluded retrograde transvenous obliteration
NBCA	N-butyl-2-cyanoacrylate	Endoscopic cyanoacrylate injection

Primary Outcome Measures

Name	Time	Method
The number of participants with failure to control acute bleeding or failure to prevent clinically significant variceal rebleeding within 1 year after enrollment	1 year

Secondary Outcome Measures

Name	Time	Method
Mortality rate	3 years
Eradication rate of gastric varices	3 years
Number of participants with increase or decrease in the size of gastric varices	3 years
Number of participants with appearance or worsening of portal hypertensive gastropathy	3 years
Number of participants with appearance or worsening of ascites	3 years
Average in-hospital stay	3 years
Number of participants with appearance or worsening of new oesophageal varices	3 years
Number of participants with complication	3 years
Cost of treatment	3 years

Trial Locations

Locations (1)

West China Hospital; 🇨🇳 Chengdu, Sichuan, China